Bicara Therapeutics Inc. · NASDAQ:BCAX
Bicara Therapeutics — Q3 2026 Earnings Presentation
10 slides from Bicara Therapeutics's earnings presentation, Nov 9, 2026
Slide 1: Q3 2026 Earnings Call
Q3 2026 Earnings Call November 9, 2026 © 2024 – 2026 Bicara Therapeutics
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements other than historical factual information are forward-looking statements, including without limitation express or implied statements regarding our strateg
Slide 3: Agenda & today's presenters
Agenda & today’s presenters 1 Introduction & Q3 2026 Highlights Ryan Cohlhepp, PharmD Interim Chief Executive Officer 2 Ficerafusp alfa (FICERA) Clinical Data Bill Schelman, MD, PhD Chief Medical Officer Chris Sarchi 2 Commercial Strategy Chief Commercial Officer Jenn Larson, CPA 3 Financial Results
Slide 4: Q3 2026 highlights and recent progress
Q3 2026 highlights and recent progress Achieved substantial enrollment in FORTIFI-HN01 pivotal trial, enabling a topline 1 interim analysis in mid-2027 Advanced FORTIFI-FLEX, our alternate dosing study to evaluate a loading and every- 2 three-week maintenance dosing regimen of FICERA + pembrolizumab
Slide 5: Three-year Phase 1b follow-up reinforces confidence in FORTIFI-HN01
Three-year Phase 1b follow-up reinforces confidence in FORTIFI-HN01 Depth of response drives durability: the hallmark of FICERA's clinical profile Duration of response by depth of response At the 1500 mg pivotal dose Pooled responders across all three dose cohorts (N=45) Deep response (≥80%), n=30 5
Slide 6: Why our data, and the context behind them, matter
Why our data, and the context behind them, matter FICERA's Phase 1b enrolled the patients who are hardest to treat 1500 mg QW pivotal-dose cohort1 Why it matters N=30 HPV-negative patients are a poorer-prognosis population in head HPV status 100% HPV-negative and neck cancer, and the only population
Slide 7: A $5B+ annual global market that FICERA is built to lead, and to grow
A $5B+ annual global market that FICERA is built to lead, and to grow HPV-negative HNSCC carries the poorest outcomes and the fewest effective options today An underserved population Deep, durable responses $5B+ 1 drive OS projected annual global HNSCC Limited response rates Deep responses sales by
Slide 8: Physician conviction is building
Physician conviction is building Market research shows a meaningful shift in how physicians view FICERA over the past year A Commercial leadership 2025 physician view 2026 physician view team built to execute Treatment approach HPV+ and HPV- inclusion slightly favored HPV- seen as a distinct disease
Slide 9: Strong financial position to support strategic investment (in millions)
Strong financial position to support strategic investment (in millions) Three Months Ended Nine Months Ended Statement of Operations September 30, September 30, (Unaudited) 2026 2025 2026 2025 Total operating expenses Research & development1 $ 56.5 $ 33.0 $ 149.7 $ 92.1 General & administrative2 $ 1
Slide 10: Thank You
BICARA THERAPEUTICS” Thank You